OBJECTIVE To determine the frequency of end treatment virologic response (ETR) with pegylated interferon alpha and ribavirin in treatment of chronic hepatitis C patients who failed to respond to interferon plus ribavirin therapy given for at least 24 weeks. STUDY DESIGN Descriptive study. PLACE AND DURATION OF STUDY Medical Unit-II, Benazir Bhutto Hospital, Shafi Clinic Rawalpindi and PAEC ...

Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon‐α monotherapy in 1992 to the approval of telaprevir‐ and boceprevir‐based triple therapies with pegylated interferon‐α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improveme...

BACKGROUND Hepatitis is a major public health problem in Pakistan due to its strong association with liver failure and hepatocellular carcinoma. In Pakistan, conventional interferon therapy along with Ribavirin is favoured especially in Government funded programs for treatment of Hepatitis C, over the more expensive Pegylated Interferon and Ribavirin combination therapy as recommended by Pakist...

PURPOSE OF REVIEW We review here the recent literature regarding hepatitis C virus (HCV) therapy through January 2013. We discuss current therapies, targets for new therapies, and what might be expected in this rapidly changing field. RECENT FINDINGS Boceprevir-based and telaprevir-based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy fo...

High-dose interferon-alpha remains the first-line treatment in the adjuvant therapy of metastatic melanoma. More recently, high-dose pegylated interferon-alpha-2b has been approved by the US Food and Drug Administration. Actually, an adjuvant therapy alternative to high-dose interferon-alpha is represented by ipilimumab. Moreover, combination therapy of IFN-alpha or ipilimumab with tyrosine kin...

BACKGROUND/AIMS Interferon treatment of malignant or viral diseases can be accompanied by various side-effects including nephro-toxicity. METHODS We report on a 68-year-old Caucasian male who received dual therapy with pegylated interferon 2a plus ribavirin for chronic hepatitis C. RESULTS After three months of antiviral therapy, the patient developed acute kidney failure (serum creatinine ...

Scr and LM, that can be correctly assessed in renal insufficient patients without DEXA, simply from anthropometrics or body impedance analysis [3], would constitute important progress for practice. However, the relationships between LM and creatinine production, and between Scr and glomerular filtration, are not simple. The formula proposed by Taylor et al. [1] leads to an important overestimat...

BACKGROUND Hepatitis D virus (HDV) infection is characterized by rapidly progressive liver disease with adverse prognosis in most patients. Although interferon is the only approved anti-HDV therapy, evidence regarding the efficacy and safety of its various regimens is either old or scattered. MATERIALS AND METHODS We searched systematically Medline, EMBASE, Scopus, the Cochrane Central Regist...

OBJECTIVE To review and compare side effects of hepatitis C treatment with pegylated interferon and ribavirin at the CRIE of the Hospital Mário Covas (Santo André), São Paulo, Brazil, from February 23 to May 5, 2011. METHODS Cross-sectional study through questionnaire, with a non-probability sample comprised of 340 patients that had received at least one dose of the medication. RESULTS Side...

BACKGROUND Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. METHODS Pa...